



## Zoledronic acid (Zometa<sup>®</sup>, Reclast<sup>®</sup>) (Intravenous)

Document Number: IC-0153

Last Review Date: 02/23/2016

Date of Origin: 06/21/2011

Dates Reviewed: 09/2011, 12/2011, 03/2012, 06/2012, 09/2012, 12/2012, 03/2013, 06/2013, 09/2013, 12/2013, 03/2014, 06/2014, 09/2014, 12/2014, 03/2015, 5/2015, 8/2015, 11/2015, 02/2016

### I. Length of Authorization

- **Zometa:** Coverage is provided for 6 months and may be renewed
- **Reclast:** Coverage is provided for 12 months and may be renewed

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [Pharmacy Benefit]:

– N/A

#### B. Max Units (per dose and over time) [Medical Benefit]:

##### Zometa

##### Hypercalcemia of malignancy:

**Male:** 4 billable units every 7 days

**Female:** 4 billable units every 7 days

##### Treatment of multiple myeloma

**Male:** 4 billable units every 21 days

**Female:** 4 billable units every 21 days

##### Treatment of bone metastases from solid tumors:

**Male:** 4 billable units every 21 days

**Female:** 4 billable units every 21 days

##### Prevention of bone loss in breast cancer

**Male:** 4 billable units every 168 days (6 months)

**Female:** 4 billable units every 168 days (6 months)

Prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer

**Male:** 4 billable units every 84 days (3 months)

**Female:** N/A

**Reclast**

Paget's disease:

**Male:** 5 billable units every 365 days (12 months)

**Female:** 5 billable units every 365 days (12 months)

Treatment/prevention of osteoporosis

**Male:** 5 billable units every 365 days (12 months)

**Female:** 5 billable units every 365 days (12 months)

Prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer

**Male:** 5 billable units every 365 days (12 months)

**Female:** N/A

### III. Initial Approval Criteria

**Zometa**

Coverage is provided in the following conditions:

- Hypercalcemia of malignancy†
- Multiple myeloma†
- Bone metastases from solid tumors†
- Prevention of skeletal related events in men with castration-recurrent prostate cancer
- Prevention of bone loss associated with aromatase inhibitor therapy in post-menopausal women with breast cancer
- Prevention of bone loss associated with androgen deprivation therapy in men with prostate cancer

**Reclast**

Coverage is provided in the following conditions:

- **Treatment and prevention of postmenopausal osteoporosis†**
  - Patient experienced severe intolerance, ineffective response±, or has contraindications\* to oral bisphosphonate therapy

- **Treatment to increase bone mass in men with osteoporosis†**
  - Patient experienced severe intolerance, ineffective response±, or has contraindications\* to oral bisphosphonate therapy
- **Treatment and prevention of glucocorticoids-induced osteoporosis†**
  - Patient experienced severe intolerance, ineffective response±, or has contraindications\* to oral bisphosphonate therapy
- **Treatment of Paget’s disease of bone in men and women†**
  - Serum alkaline phosphatase is two times or higher than the upper limit of the age-specific reference range; **OR**
  - Patient is symptomatic; **OR**
  - Patient is a risk for complications from their disease
- **Prevention or treatment of osteoporosis in men with prostate cancer during androgen deprivation therapy**

±Ineffective response is defined as one of the following:

- Decrease in T-score in comparison with baseline T-score from DXA scan
- Patient has a new fracture while on bisphosphonate therapy

\*Contraindication to oral bisphosphonate therapy is defined as one of the following:

- Documented inability to sit or stand upright for at least 30 minutes
- Documented pre-existing gastrointestinal disorder such as inability to swallow, Barrett’s esophagus, esophageal stricture, dysmotility, or achalasia

†FDA Approved Indication(s)

#### IV. Renewal Criteria

Authorizations can be renewed based on the following criteria:

##### (Oncology)

- Tumor response with stabilization of disease or decrease in size of tumor; **AND**
- Absence of unacceptable toxicity from the drug

##### (Non-Oncology)

- Patient continues to meet criteria identified in section III; **AND**
- Disease response; **AND**
- Absence of unacceptable toxicity from the drug

#### V. Dosage/Administration

Indication	Dose
------------	------

<b>Zometa</b>	
Hypercalcemia of malignancy	4mg IV x 1 dose, may be repeated after 7 days if serum calcium does not return to normal
Prevention of aromatase inhibitor-induced bone loss in breast cancer	4mg every 6 months
Prevention of androgen deprivation-induced bone loss in prostate cancer	4mg – 5mg every 3 to 12 months
All other indications	4mg IV every 3 to 4 weeks
<b>Reclast</b>	
Active Paget's Disease	5 mg x 1 dose
Prevention of osteoporosis in post-menopausal women	5 mg every 2 years
Prevention of glucocorticoid-induced osteoporosis	5 mg every year
Treatment of osteoporosis	5 mg every year

## VI. Billing Code/Availability Information

### Jcode:

- J3489 - Zometa\*\* (Novartis) 4 mg Injection: 1 billable unit = 1 mg
- J3489 - Reclast\*\* (Novartis) 5 mg Injection: 1 billable unit = 1 mg

\*\*Generic available

### NDC:

- N/A

## VII. References

1. Zometa [package insert]. Stein, Switzerland; Novartis Pharmaceuticals; January 2015. Accessed January 2016.
2. Reclast [package insert]. East Hanover, NJ; Novartis Pharmaceuticals; January 2015. Accessed January 2016.
3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Zoledronic Acid. National Comprehensive Cancer Network, 2016. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc.” To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed January 2016.

4. Bhoopalam, N. et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. *J Urol*. 2009 Nov;182(5):2257-64. Epub 2009 Sep 16.
5. Bundred, N.J. et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. *Cancer*. 2008 Mar 1;112(5):1001-10.
6. Brufsky A, Harker WG, Beck JT, et al, “Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer,” *J Clin Oncol* 2007, 25(7):829-36.
7. Himelstein AL, Qin R, Novotny PJ, et al. “CALBG 70604 (Alliance): A randomized phase III study of standard dosing vs longer interval dosing of zoledronic acid in metastatic cancer. *J Clin Oncol* 33, 2015 (suppl; abstr 9501).
8. Wisconsin Physicians Service Insurance Corporation. Local Coverage Determination (LCD) for Bisphosphonate Drug Therapy (L34648). Centers for Medicare & Medicaid Services. Updated on 10/1/2015 with effective date 10/1/2015. Accessed January 2016.
9. First Coast Service Options, Inc. Local Coverage Determination (LCD) for Bisphosphonates (Intravenous [IV]) and Monoclonal Antibodies in the Treatment of Osteoporosis and Their Other Indications (L33270). Centers for Medicare & Medicaid Services, Inc. Updated on 10/1/2015 with effective date 10/1/2015. Accessed January 2016.
10. Cahaba Government Benefit Administrators, LLC. Local Coverage Determination (LCD) for Drugs and Biologicals: Zoledronic Acid (L34260). Centers for Medicare & Medicaid Services, Inc. Updated on 10/1/2015 with effective date 10/1/2015. Accessed January 2016.
11. National Government Services, Inc. Local Coverage Article for ZOLEDRONIC Acid (e.g., Zometa®, Reclast®) – Related to LCD L33394 (A52455). Centers for Medicare & Medicaid Services. Updated on 10/1/2015 with effective date 10/1/2015. Accessed January 2016.

## Appendix 1 – Covered Diagnosis Codes

### Zometa

ICD-9 Codes	Diagnosis
140-149	Malignant neoplasm of lip, oral cavity and pharynx
150-159	Malignant Neoplasm Of Digestive Organs And Peritoneum
160-165	Malignant Neoplasm Of Respiratory And Intrathoracic Organs
170-176	Malignant Neoplasm Of Bone, Connective Tissue, Skin, And Breast
179-189	Malignant Neoplasm Of Genitourinary Organs
190-199	Malignant Neoplasm Of Other And Unspecified Sites
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue
201	Hodgkin's disease

ICD-9 Codes	Diagnosis
202	Other malignant neoplasms of lymphoid and histiocytic tissue
203.00	Multiple myeloma, without mention of having achieved remission
203.02	Multiple myeloma, in relapse
203.10	Plasma cell leukemia, without mention of having achieved remission
203.12	Plasma cell leukemia, in relapse
203.80	Other immunoproliferative neoplasms, without mention of having achieved remission
203.82	Other immunoproliferative neoplasms, in relapse
209	Neuroendocrine tumors
230-234	Carcinoma In Situ
235-238	Neoplasms Of Uncertain Behavior
239-239	Neoplasms Of Unspecified Nature
259.2	Carcinoid syndrome
275.42	Hypercalcemia
733.09	Other osteoporosis
733.90	Disorder of bone and cartilage, unspecified
V10.09	Personal history of malignant neoplasm of other gastrointestinal tract
V10.52	Personal history of malignant neoplasm of kidney
V10.79	Personal history of other lymphatic and hematopoietic neoplasms
V10.89	Personal history of malignant neoplasm of other sites
V10.91	Personal history of malignant neuroendocrine tumor

**Dual coding requirements:**

Prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer:

- Primary code: 733.90 or 733.09 plus the following Secondary code: 185

Prevention of bone loss in breast cancer

- Primary code: 733.90 plus one of the following Secondary codes: 174.0-175.9

ICD-10	ICD-10 Description
C00-C14	Malignant neoplasms of lip, oral cavity and pharynx
C15-C26	Malignant neoplasms of digestive organs
C30-C39	Malignant neoplasms of respiratory and intrathoracic organs
C40-C41	Malignant neoplasms of bone and articular cartilage
C43-C44	Melanoma and other malignant neoplasms of skin
C45-C49	Malignant neoplasms of mesothelial and soft tissue
C50-C50	Malignant neoplasms of breast
C51-C58	Malignant neoplasms of female genital organs
C60-C63	Malignant neoplasms of male genital organs

ICD-10	ICD-10 Description
C64-C68	Malignant neoplasms of urinary tract
C69-C72	Malignant neoplasms of eye, brain and other parts of central nervous system
C73-C75	Malignant neoplasms of thyroid and other endocrine glands
C7A-C7A	Malignant neuroendocrine tumors
C7B-C7B	Secondary neuroendocrine tumors
C76-C80	Malignant neoplasms of ill-defined, other secondary and unspecified sites
C81	Hodgkin lymphoma
C82	Follicular lymphoma
C83	Non-follicular lymphoma
C84	Mature T/NK-cell lymphomas
C85	Other specified and unspecified types of non-Hodgkin lymphoma
C86	Other specified types of T/NK-cell lymphoma
C88	Malignant immunoproliferative diseases and certain other B-cell lymphomas
C90.00	Multiple myeloma not having reached remission
C90.02	Multiple myeloma in relapse
C90.10	Plasma cell leukemia not having reached remission
C90.12	Plasma cell leukemia in relapse
C90.20	Extramedullary plasmacytoma not having reached remission
C90.22	Extramedullary plasmacytoma in relapse
C90.30	Solitary plasmacytoma not having reached remission
C90.32	Solitary plasmacytoma in relapse
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue
D00-D09	In situ neoplasms
D10-D36	Benign neoplasms, except benign neuroendocrine tumors
D3A-D3A	Benign neuroendocrine tumors
D37	Neoplasm of uncertain behavior of oral cavity and digestive organs
D38	Neoplasm of uncertain behavior of middle ear and respiratory and intrathoracic organs
D39	Neoplasm of uncertain behavior of female genital organs
D40	Neoplasm of uncertain behavior of male genital organs
D41	Neoplasm of uncertain behavior of urinary organs
D42	Neoplasm of uncertain behavior of meninges
D43	Neoplasm of uncertain behavior of brain and central nervous system
D44	Neoplasm of uncertain behavior of endocrine glands
D48	Neoplasm of uncertain behavior of other and unspecified sites

ICD-10	ICD-10 Description
D49-D49	Neoplasms of unspecified behavior
E83.52	Hypercalcemia
Z85	Personal history of malignant neoplasm

**Dual coding requirements:**

Prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer:

- Primary code: M89.9, M94.9 or M81.8 plus the following Secondary code: C61

Prevention of bone loss in breast cancer

- Primary code: M89.9 or M94.9 plus one of the following Secondary codes: C50.19 – C50.929

**Reclast**

ICD-9 Codes	Diagnosis
185	Malignant neoplasm of prostate
731.0	Osteitis deformans without mention of bone tumor
733.00	Osteoporosis, unspecified
733.01	Senile osteoporosis
733.02	Idiopathic osteoporosis
733.03	Disuse osteoporosis
733.09	Other osteoporosis
733.90	Disorder of bone and cartilage, unspecified

Dual coding requirement for prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer:

- Primary code: 733.90 or 733.09 plus the following Secondary code: 185

ICD-10	ICD-10 Description
C61	Malignant neoplasm of prostate
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis
M81.8	Other osteoporosis without current pathological fracture
M85.80	Other specified disorders of bone density and structure, unspecified site
M85.851	Other specified disorders of bone density and structure, right thigh
M85.852	Other specified disorders of bone density and structure, left thigh
M85.859	Other specified disorders of bone density and structure, unspecified thigh
M85.88	Other specified disorders of bone density and structure, other site
M85.89	Other specified disorders of bone density and structure, multiple sites
M85.9	Disorder of bone density and structure, unspecified
M88.0	Osteitis deformans of skull
M88.1	Osteitis deformans of vertebrae
M88.811	Osteitis deformans of right shoulder



ICD-10	ICD-10 Description
M88.812	Osteitis deformans of left shoulder
M88.819	Osteitis deformans of unspecified shoulder
M88.821	Osteitis deformans of right upper arm
M88.822	Osteitis deformans of left upper arm
M88.829	Osteitis deformans of unspecified upper arm
M88.831	Osteitis deformans of right forearm
M88.832	Osteitis deformans of left forearm
M88.839	Osteitis deformans of unspecified forearm
M88.841	Osteitis deformans of right hand
M88.842	Osteitis deformans of left hand
M88.849	Osteitis deformans of unspecified hand
M88.851	Osteitis deformans of right thigh
M88.852	Osteitis deformans of left thigh
M88.859	Osteitis deformans of unspecified thigh
M88.861	Osteitis deformans of right lower leg
M88.862	Osteitis deformans of left lower leg
M88.869	Osteitis deformans of unspecified leg
M88.871	Osteitis deformans of right ankle
M88.872	Osteitis deformans of left ankle
M88.879	Osteitis deformans of unspecified ankle
M88.88	Osteitis deformans of other bone
M88.89	Osteitis deformans of multiple sites
M88.9	Osteitis deformans of unspecified bone
M89.9	Disorder of bone, unspecified
M94.9	Disorder of cartilage, unspecified

Dual coding requirement for prevention of bone loss in prostate cancer/ Prevention or treatment of osteoporosis in prostate cancer:

- Primary code: M85.8x, M89.9, M94.9 or M81.8 plus the following Secondary code: C61

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD):

## Zometa

<b>Jurisdiction(s):</b> 5, 8	<b>NCD/LCD Document (s):</b> L34648
------------------------------	-------------------------------------

ICD-10 Codes	Diagnosis
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse
E83.52	Hypercalcemia
M61.011	Myositis ossificans traumatica, right shoulder
M61.012	Myositis ossificans traumatica, left shoulder
M61.021	Myositis ossificans traumatica, right upper arm
M61.022	Myositis ossificans traumatica, left upper arm
M61.031	Myositis ossificans traumatica, right forearm
M61.032	Myositis ossificans traumatica, left forearm
M61.041	Myositis ossificans traumatica, right hand
M61.042	Myositis ossificans traumatica, left hand
M61.051	Myositis ossificans traumatica, right thigh
M61.052	Myositis ossificans traumatica, left thigh
M61.061	Myositis ossificans traumatica, right lower leg
M61.062	Myositis ossificans traumatica, left lower leg
M61.071	Myositis ossificans traumatica, right ankle and foot
M61.072	Myositis ossificans traumatica, left ankle and foot
M61.08	Myositis ossificans traumatica, other site
M61.09	Myositis ossificans traumatica, multiple sites
M61.111	Myositis ossificans progressiva, right shoulder
M61.112	Myositis ossificans progressiva, left shoulder
M61.121	Myositis ossificans progressiva, right upper arm
M61.122	Myositis ossificans progressiva, left upper arm
M61.131	Myositis ossificans progressiva, right forearm
M61.132	Myositis ossificans progressiva, left forearm
M61.141	Myositis ossificans progressiva, right hand
M61.142	Myositis ossificans progressiva, left hand
M61.144	Myositis ossificans progressiva, right finger(s)

ICD-10 Codes	Diagnosis
M61.145	Myositis ossificans progressiva, left finger(s)
M61.151	Myositis ossificans progressiva, right thigh
M61.152	Myositis ossificans progressiva, left thigh
M61.161	Myositis ossificans progressiva, right lower leg
M61.162	Myositis ossificans progressiva, left lower leg
M61.171	Myositis ossificans progressiva, right ankle
M61.172	Myositis ossificans progressiva, left ankle
M61.174	Myositis ossificans progressiva, right foot
M61.175	Myositis ossificans progressiva, left foot
M61.177	Myositis ossificans progressiva, right toe(s)
M61.178	Myositis ossificans progressiva, left toe(s)
M61.18	Myositis ossificans progressiva, other site
M61.19	Myositis ossificans progressiva, multiple sites
M61.211	Paralytic calcification and ossification of muscle, right shoulder
M61.212	Paralytic calcification and ossification of muscle, left shoulder
M61.221	Paralytic calcification and ossification of muscle, right upper arm
M61.222	Paralytic calcification and ossification of muscle, left upper arm
M61.231	Paralytic calcification and ossification of muscle, right forearm
M61.232	Paralytic calcification and ossification of muscle, left forearm
M61.241	Paralytic calcification and ossification of muscle, right hand
M61.242	Paralytic calcification and ossification of muscle, left hand
M61.251	Paralytic calcification and ossification of muscle, right thigh
M61.252	Paralytic calcification and ossification of muscle, left thigh
M61.261	Paralytic calcification and ossification of muscle, right lower leg
M61.262	Paralytic calcification and ossification of muscle, left lower leg
M61.271	Paralytic calcification and ossification of muscle, right ankle and foot
M61.272	Paralytic calcification and ossification of muscle, left ankle and foot
M61.28	Paralytic calcification and ossification of muscle, other site
M61.29	Paralytic calcification and ossification of muscle, multiple sites
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis [Lequesne]
M81.8	Other osteoporosis without current pathological fracture
M88.0	Osteitis deformans of skull
M88.1	Osteitis deformans of vertebrae

ICD-10 Codes	Diagnosis
M88.811	Osteitis deformans of right shoulder
M88.812	Osteitis deformans of left shoulder
M88.821	Osteitis deformans of right upper arm
M88.822	Osteitis deformans of left upper arm
M88.831	Osteitis deformans of right forearm
M88.832	Osteitis deformans of left forearm
M88.841	Osteitis deformans of right hand
M88.842	Osteitis deformans of left hand
M88.851	Osteitis deformans of right thigh
M88.852	Osteitis deformans of left thigh
M88.861	Osteitis deformans of right lower leg
M88.862	Osteitis deformans of left lower leg
M88.871	Osteitis deformans of right ankle and foot
M88.872	Osteitis deformans of left ankle and foot
M88.88	Osteitis deformans of other bones
M88.89	Osteitis deformans of multiple sites
T79.6XXA	Traumatic ischemia of muscle, initial encounter

### Reclast

<b>Jurisdiction(s):</b> 5, 8	<b>NCD/LCD Document (s):</b> L34648
------------------------------	-------------------------------------

ICD-10 Codes	Diagnosis
C79.51	Secondary malignant neoplasm of bone
C79.52	Secondary malignant neoplasm of bone marrow
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse
E83.52	Hypercalcemia
M61.011	Myositis ossificans traumatica, right shoulder
M61.012	Myositis ossificans traumatica, left shoulder
M61.021	Myositis ossificans traumatica, right upper arm
M61.022	Myositis ossificans traumatica, left upper arm
M61.031	Myositis ossificans traumatica, right forearm
M61.032	Myositis ossificans traumatica, left forearm
M61.041	Myositis ossificans traumatica, right hand

M61.042	Myositis ossificans traumatica, left hand
M61.051	Myositis ossificans traumatica, right thigh
M61.052	Myositis ossificans traumatica, left thigh
M61.061	Myositis ossificans traumatica, right lower leg
M61.062	Myositis ossificans traumatica, left lower leg
M61.071	Myositis ossificans traumatica, right ankle and foot
M61.072	Myositis ossificans traumatica, left ankle and foot
M61.08	Myositis ossificans traumatica, other site
M61.09	Myositis ossificans traumatica, multiple sites
M61.111	Myositis ossificans progressiva, right shoulder
M61.112	Myositis ossificans progressiva, left shoulder
M61.121	Myositis ossificans progressiva, right upper arm
M61.122	Myositis ossificans progressiva, left upper arm
M61.131	Myositis ossificans progressiva, right forearm
M61.132	Myositis ossificans progressiva, left forearm
M61.141	Myositis ossificans progressiva, right hand
M61.142	Myositis ossificans progressiva, left hand
M61.144	Myositis ossificans progressiva, right finger(s)
M61.145	Myositis ossificans progressiva, left finger(s)
M61.151	Myositis ossificans progressiva, right thigh
M61.152	Myositis ossificans progressiva, left thigh
M61.161	Myositis ossificans progressiva, right lower leg
M61.162	Myositis ossificans progressiva, left lower leg
M61.171	Myositis ossificans progressiva, right ankle
M61.172	Myositis ossificans progressiva, left ankle
M61.174	Myositis ossificans progressiva, right foot
M61.175	Myositis ossificans progressiva, left foot
M61.177	Myositis ossificans progressiva, right toe(s)
M61.178	Myositis ossificans progressiva, left toe(s)
M61.18	Myositis ossificans progressiva, other site
M61.19	Myositis ossificans progressiva, multiple sites
M61.211	Paralytic calcification and ossification of muscle, right shoulder
M61.212	Paralytic calcification and ossification of muscle, left shoulder
M61.221	Paralytic calcification and ossification of muscle, right upper arm
M61.222	Paralytic calcification and ossification of muscle, left upper arm

M61.231	Paralytic calcification and ossification of muscle, right forearm
M61.232	Paralytic calcification and ossification of muscle, left forearm
M61.241	Paralytic calcification and ossification of muscle, right hand
M61.242	Paralytic calcification and ossification of muscle, left hand
M61.251	Paralytic calcification and ossification of muscle, right thigh
M61.252	Paralytic calcification and ossification of muscle, left thigh
M61.261	Paralytic calcification and ossification of muscle, right lower leg
M61.262	Paralytic calcification and ossification of muscle, left lower leg
M61.271	Paralytic calcification and ossification of muscle, right ankle and foot
M61.272	Paralytic calcification and ossification of muscle, left ankle and foot
M61.28	Paralytic calcification and ossification of muscle, other site
M61.29	Paralytic calcification and ossification of muscle, multiple sites
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis [Lequesne]
M81.8	Other osteoporosis without current pathological fracture
M88.0	Osteitis deformans of skull
M88.1	Osteitis deformans of vertebrae
M88.811	Osteitis deformans of right shoulder
M88.812	Osteitis deformans of left shoulder
M88.821	Osteitis deformans of right upper arm
M88.822	Osteitis deformans of left upper arm
M88.831	Osteitis deformans of right forearm
M88.832	Osteitis deformans of left forearm
M88.841	Osteitis deformans of right hand
M88.842	Osteitis deformans of left hand
M88.851	Osteitis deformans of right thigh
M88.852	Osteitis deformans of left thigh
M88.861	Osteitis deformans of right lower leg
M88.862	Osteitis deformans of left lower leg
M88.871	Osteitis deformans of right ankle and foot
M88.872	Osteitis deformans of left ankle and foot
M88.88	Osteitis deformans of other bones
M88.89	Osteitis deformans of multiple sites
T79.6XXA	Traumatic ischemia of muscle, initial encounter

## Zometa

### ZOLEDRONIC ACID (Zometa®, Reclast®) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2015, Magellan Rx Management

**MagellanRx**  
MANAGEMENT™

<b>Jurisdiction(s):</b> 9(N)	<b>NCD/LCD Document (s):</b> L33270
<b>ICD-10 Codes</b>	<b>Diagnosis</b>
C79.51 – C79.52	Secondary malignant neoplasm of bone - Secondary malignant neoplasm of bone marrow
C90.00 – C90.02	Multiple myeloma not having achieved remission - Multiple myeloma in relapse
E83.52	Hypercalcemia
M89.9	Disorder of bone, unspecified
M94.9	Disorder of cartilage, unspecified

### Reclast

<b>Jurisdiction(s):</b> 9(N)	<b>NCD/LCD Document (s):</b> L33270
<b>ICD-10 Codes</b>	<b>Diagnosis</b>
M81.0	Age-related osteoporosis without current pathological fracture
M81.6 – M81.8*	Localized osteoporosis [Lequesne] - Other osteoporosis without current pathological fracture
M88.1 – M88.9	Osteitis deformans of vertebrae - Osteitis deformans of unspecified bone
T38.0X5A – T38.0X5S*	Adverse effect of glucocorticoids and synthetic analogues, initial encounter - Adverse effect of glucocorticoids and synthetic analogues, sequela
T50.0X5A – T50.0X5S*	Adverse effect of mineralocorticoids and their antagonists, initial encounter - Adverse effect of mineralocorticoids and their antagonists, sequela

\*When reporting ICD-10-CM code M81.6 or M81.8, ICD-10-CM code T38.0X5A, T38.0X5D, T38.0X5S, T50.0X5A, T50.0X5D or T50.0X5S must also be reported.

### Zometa

<b>Jurisdiction(s):</b> 10 (J)	<b>NCD/LCD Document (s):</b> L34260
<b>ICD-10 Codes</b>	<b>Diagnosis</b>
C00.0 – C43.9	Malignant neoplasm of external upper lip - Malignant melanoma of skin, unspecified
C4A.0 – C4A.9	Merkel cell carcinoma of lip - Merkel cell carcinoma, unspecified
C44.00 – C49.9	Unspecified malignant neoplasm of skin of lip - Malignant neoplasm of connective and soft tissue, unspecified
C50.011 – C75.9	Malignant neoplasm of nipple and areola, right female breast - Malignant neoplasm of endocrine gland, unspecified

ICD-10 Codes	Diagnosis
C7A.00 – C7B.8	Malignant carcinoid tumor of unspecified site - Other secondary neuroendocrine tumors
C76.0 – C79.9	Malignant neoplasm of head, face and neck - Secondary malignant neoplasm of unspecified site
C80.0 – C84.79	Disseminated malignant neoplasm, unspecified - Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
C84.A0 – C84.Z9	Cutaneous T-cell lymphoma, unspecified, unspecified site - Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C84.90 – C84.99	Mature T/NK-cell lymphomas, unspecified, unspecified site - Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C85.10 – C86.6	Unspecified B-cell lymphoma, unspecified site - Primary cutaneous CD30-positive T-cell proliferations
C88.2 – C91.62	Heavy chain disease - Prolymphocytic leukemia of T-cell type, in relapse
C91.A0 – C91.Z2	Mature B-cell leukemia Burkitt-type not having achieved remission - Other lymphoid leukemia, in relapse
C91.90 – C91.92	Lymphoid leukemia, unspecified not having achieved remission - Lymphoid leukemia, unspecified, in relapse
C92.00 – C92.62	Acute myeloblastic leukemia, not having achieved remission - Acute myeloid leukemia with 11q23-abnormality in relapse
C92.A0 – C92.Z2	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission - Other myeloid leukemia, in relapse
C92.90 – C92.92	Myeloid leukemia, unspecified, not having achieved remission - Myeloid leukemia, unspecified in relapse
C93.00 – C93.32	Acute monoblastic/monocytic leukemia, not having achieved remission - Juvenile myelomonocytic leukemia, in relapse
C93.Z0 – C93.Z2	Other monocytic leukemia, not having achieved remission - Other monocytic leukemia, in relapse
C93.90 – C93.92	Monocytic leukemia, unspecified, not having achieved remission - Monocytic leukemia, unspecified in relapse
C94.00 – C94.32	Acute erythroid leukemia, not having achieved remission - Mast cell leukemia, in relapse
C94.80 – C96.4	Other specified leukemias not having achieved remission - Sarcoma of dendritic cells (accessory cells)
C96.A – C96.Z	Histiocytic sarcoma - Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
D03.0 – D03.9	Melanoma in situ of lip - Melanoma in situ, unspecified



ICD-10 Codes	Diagnosis
D45	Polycythemia vera
E83.52	Hypercalcemia
M81.0 – M81.8	Age-related osteoporosis without current pathological fracture - Other osteoporosis without current pathological fracture
M85.9	Disorder of bone density and structure, unspecified
M88.0 – M88.9	Osteitis deformans of skull - Osteitis deformans of unspecified bone
M89.9	Disorder of bone, unspecified

### Reclast

<b>Jurisdiction(s):</b> 10 (J)	<b>NCD/LCD Document (s):</b> L34260
--------------------------------	-------------------------------------

ICD-10 Codes	Diagnosis
C00.0 – C43.9	Malignant neoplasm of external upper lip - Malignant melanoma of skin, unspecified
C4A.0 – C4A.9	Merkel cell carcinoma of lip - Merkel cell carcinoma, unspecified
C44.00 – C49.9	Unspecified malignant neoplasm of skin of lip - Malignant neoplasm of connective and soft tissue, unspecified
C50.011 – C75.9	Malignant neoplasm of nipple and areola, right female breast - Malignant neoplasm of endocrine gland, unspecified
C7A.00 – C7B.8	Malignant carcinoid tumor of unspecified site - Other secondary neuroendocrine tumors
C76.0 – C79.9	Malignant neoplasm of head, face and neck - Secondary malignant neoplasm of unspecified site
C80.0 – C84.79	Disseminated malignant neoplasm, unspecified - Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites
C84.A0 – C84.Z9	Cutaneous T-cell lymphoma, unspecified, unspecified site - Other mature T/NK-cell lymphomas, extranodal and solid organ sites
C84.90 – C84.99	Mature T/NK-cell lymphomas, unspecified, unspecified site - Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites
C85.10 – C86.6	Unspecified B-cell lymphoma, unspecified site - Primary cutaneous CD30-positive T-cell proliferations
C88.2 – C91.62	Heavy chain disease - Prolymphocytic leukemia of T-cell type, in relapse
C91.A0 – C91.Z2	Mature B-cell leukemia Burkitt-type not having achieved remission - Other lymphoid leukemia, in relapse
C91.90 – C91.92	Lymphoid leukemia, unspecified not having achieved remission - Lymphoid leukemia, unspecified, in relapse
C92.00 – C92.62	Acute myeloblastic leukemia, not having achieved remission - Acute myeloid leukemia with 11q23-abnormality in relapse

ICD-10 Codes	Diagnosis
C92.A0 – C92.Z2	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission - Other myeloid leukemia, in relapse
C92.90 – C92.92	Myeloid leukemia, unspecified, not having achieved remission - Myeloid leukemia, unspecified in relapse
C93.00 – C93.32	Acute monoblastic/monocytic leukemia, not having achieved remission - Juvenile myelomonocytic leukemia, in relapse
C93.Z0 – C93.Z2	Other monocytic leukemia, not having achieved remission - Other monocytic leukemia, in relapse
C93.90 – C93.92	Monocytic leukemia, unspecified, not having achieved remission - Monocytic leukemia, unspecified in relapse
C94.00 – C94.32	Acute erythroid leukemia, not having achieved remission - Mast cell leukemia, in relapse
C94.80 – C96.4	Other specified leukemias not having achieved remission - Sarcoma of dendritic cells (accessory cells)
C96.A – C96.Z	Histiocytic sarcoma - Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
D03.0 – D03.9	Melanoma in situ of lip - Melanoma in situ, unspecified
D45	Polycythemia vera
E83.52	Hypercalcemia
M81.0 – M81.8	Age-related osteoporosis without current pathological fracture - Other osteoporosis without current pathological fracture
M85.9	Disorder of bone density and structure, unspecified
M88.0 – M88.9	Osteitis deformans of skull - Osteitis deformans of unspecified bone
M89.9	Disorder of bone, unspecified

### Zometa/Reclast

<b>Jurisdiction(s):</b> 6, K	<b>NCD/LCD Document (s):</b> A52455
------------------------------	-------------------------------------

ICD-10 Codes	Diagnosis
C79.51	Secondary malignant neoplasm of bone
C90.00	Multiple myeloma not having achieved remission
C90.01	Multiple myeloma in remission
C90.02	Multiple myeloma in relapse
E83.52	Hypercalcemia
M80.00XA – M80.88XS	Age-related osteoporosis with current pathological fracture, unspecified site, initial encounter for fracture - Other osteoporosis with current

ICD-10 Codes	Diagnosis
	pathological fracture, vertebra(e), sequela
M81.0	Age-related osteoporosis without current pathological fracture
M81.6	Localized osteoporosis [Lequesne]
M81.8	Other osteoporosis without current pathological fracture
M85.80	Other specified disorders of bone density and structure, unspecified site
M85.831	Other specified disorders of bone density and structure, right forearm
M85.832	Other specified disorders of bone density and structure, left forearm
M85.839	Other specified disorders of bone density and structure, unspecified forearm
M85.851	Other specified disorders of bone density and structure, right thigh
M85.852	Other specified disorders of bone density and structure, left thigh
M85.859	Other specified disorders of bone density and structure, unspecified thigh
M85.88	Other specified disorders of bone density and structure, other site
M85.89	Other specified disorders of bone density and structure, multiple sites
M85.9	Disorder of bone density and structure, unspecified
M88.0 – M88.9	Osteitis deformans of skull - Osteitis deformans of unspecified bone
M89.9	Disorder of bone, unspecified

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E	CA, HI, NV, AS, GU, CNMI	Noridian Administrative Services (NAS)
F	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Administrative Services (NAS)
5	KS, NE, IA, MO	Wisconsin Physicians Service (WPS)
6	MN, WI, IL	National Government Services (NGS)
H	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions
8	MI, IN	Wisconsin Physicians Service (WPS)
9 (N)	FL, PR, VI	First Coast Service Options
10 (J)	TN, GA, AL	Cahaba Government Benefit Administrators
11 (M)	NC, SC, VA, WV	Palmetto GBA
12 (L)	DE, MD, PA, NJ, DC	Novitas Solutions
K	NY, CT, MA, RI, VT, ME, NH	National Government Services (NGS)
15	KY, OH	CGS Administrators, LLC